Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Hofseth Biocare ASA ( (HOFBF) ).
Hofseth BioCare ASA reported a 15% year-over-year increase in total operating revenues for Q1 2025, reaching NOK 60.9 million, driven by growth in human and pet health segments despite production constraints and commodity market pressures. The company is expanding its production capacity and has launched a bond in Switzerland, Lichtenstein, and Norway. Key highlights include strong B2B sales growth, participation in international expos, and significant advances in pharmaceutical research, positioning HBC as a leader in marine-based nutrition and health solutions.
More about Hofseth Biocare ASA
Hofseth BioCare ASA is a Norwegian company specializing in consumer and pet health products, emphasizing sustainability and optimal resource utilization. The company transforms salmon industry by-products into health-enhancing ingredients such as ProGo®, OmeGo®, and CalGo®/NT-II®, which offer benefits like improved iron metabolism, immune health, and joint support. HBC is headquartered in Ålesund, Norway, with additional offices in Oslo, London, Zürich, New Jersey, and Palo Alto, and is listed on the Oslo Stock Exchange.
Average Trading Volume: 91,148
Current Market Cap: NOK957.8M
Find detailed analytics on HOFBF stock on TipRanks’ Stock Analysis page.